Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) has announced that the U.S. Food and Drug Administration has approved its Investigational New Drug (IND) application for Lucid-MS (Lucid-21-302), clearing the way for the company to advance this first-in-class multiple sclerosis (MS) candidate into Phase 2 clinical development. This regulatory milestone is significant as it moves a potential new therapeutic approach for MS from early-stage testing to a pivotal efficacy trial.
The upcoming Phase 2 study is designed as a randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of Lucid-MS in people with MS, using both clinical and radiological outcome measures. The company has initiated trial start-up activities, including site selection, and expects to begin patient enrollment and drug administration as quickly as possible. This progression is crucial for determining whether Lucid-MS can offer tangible benefits to patients.
What sets Lucid-MS apart is its mechanism of action. Unlike existing MS therapies that primarily modulate the immune system to reduce inflammation, Lucid-MS is designed to provide neuroprotection by inhibiting demyelination—the process that damages the protective myelin sheath around nerve fibers. Specifically, it targets protein arginine deiminase 2 (PAD2), an enzyme implicated in myelin degradation. Preclinical models have shown that Lucid-MS can prevent and even reverse myelin breakdown, suggesting a potential to restore neurological function rather than merely slowing disease progression.
The FDA's clearance is based on a favorable safety profile observed in Phase 1 trials, where Lucid-MS was well tolerated in healthy participants. This advancement is particularly timely given the substantial unmet need for therapies that not only manage symptoms but also address the underlying neurodegenerative processes in MS.
Quantum BioPharma's financial position appears stable, with over $10 million in cash, digital assets, and liquid investments reported as of March 31, 2026, which could support the upcoming trial. The company's broader pipeline, including its interest in Unbuzzd, underscores its commitment to addressing challenging neurological and metabolic disorders.
For the full press release, visit here. More information about Quantum BioPharma's news and updates can be found in their newsroom.
